Litcius/Paper detail

Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis

Patrick Rossignol, Faïez Zannad, Ziad Massy, Michel Azizi, Fatima Chorfa, Julien Coadic, João Pedro Ferreira, Francisca Saraiva, Dominique Mottier, Françis Guillemin, Willy Ngueyon Sime, Sanae Bouali, Bénédicte Rossignol, Joëlle Nortier, Isabelle Simon, Christophe Robino, Manuela Davin, Pierre Bataille, François Chantrel, Nelly Castin, Vincent Esnault, Isabelle Kazès, Thierry Hannedouche, Nassim Kamar, Jean‐Michel Achard, Caroline Fenerol, Carine Achard-Hottelart, Yves Dimitrov, Nicolas Girerd, Delphine Maucourt-Boulch, Luc Frimat, Luc Frimat, Jean-Michel Achard, Carine Achard Hottelart, Didier Aguilera, Asma Alla, Vincent Allot, Mahmoud Allouache, Walid Arkouche, Michel Azizi, Daniela Babici, Nolwenn Bacle-Rabot, Jean-Louis Bacri, Aurore Barthelemy, Grégoire Basse, Pierre Bataille, Stanislas Bataille, Dorothée Bazin-Kara, Clémence Bechade, Stefanie Beier, Larbi Bencheikh, Jean-Christophe Bendini, Valérie Betz, Pascal Bindi, Béatrice Birmele, Vincent Bisaccia, Laurène Blacher, Frédérique Bocquentin, Claire Borni Duval, Alexandra Botte, Sanae Bouali, Julien Bouet, Rehouni Boulahrouz, Franck Bourdon, Antoine Braconnier, Philippe Brunet, Flora Brunner, Thanh Cao-Huu, Claire Cartery, Nelly Castin, Etienne Cellot, Jean-Marc Chalopin, Jacques Chanliau, François Chantrel, Marion Chapal, Christophe Charasse, Emmanuelle Charlin, Vianney Charpy, Fatima Chorfa, Gabriel Choukroun, Pierre Clavel, Julien Coadic, Jean-Marie Coulibaly, Grégoire Couvrat-Desvergnes, Joëlle Cridlig, Romain Crochette, Géraldine d'Ythurbide, Maite Daroux, Manuela Davin, Géraldine De Geyer d'Orth, Louis De Laforcade, Melanie Decambron, Vincent Delattre, Arnaud Delbello, Catherine Delcroix, Carole Deprele, Jonathan Desprez, Nadège Devillard, Mohamed Diab Mahoumoud, Zara Dickson

2025The Lancet24 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSpironolactonePopulationInternal medicinePlaceboAdverse effectClinical endpointKidney diseaseRandomized controlled trialHeart failureDialysisStroke (engine)Environmental healthMechanical engineeringAlternative medicinePathologyEngineeringHormonal Regulation and HypertensionAdrenal Hormones and DisordersIon Transport and Channel Regulation
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis | Litcius